Tanmeyah, a subsidiary of EFG Holding, has partnered with digital healthcare solutions provider eHealth and eAswaaq, a subsidiary of e-finance for Digital and Financial Investments, to combine financing with technology in a single bundled offering for healthcare providers.

The deal was announced via a press release on June 17, 2026. It puts three different capabilities under one roof: credit, software, and distribution.

How will it work?

Each company brings a specific role to the table:

• Tanmeyah will provide financing products designed specifically for healthcare providers, including clinics and small medical centers.
• eHealth will supply its “Eyada Plus” platform, a management system for running medical facilities.
• eAswaaq will handle marketing and distribution, using its existing digital platforms and sales channels to reach providers across Egypt.

The bundled model lets healthcare providers finance the cost of subscribing to the Eyada Plus platform directly through Tanmeyah. That means a clinic does not need to find separate funding before it can adopt the software. The subscription cost is folded into a financing arrangement, so the provider pays over time rather than upfront.

The three companies also plan to build a shared electronic platform where healthcare providers can apply for financing and manage their subscriptions in one place.

Why does it matter?

Small clinics and independent medical centers in Egypt often run on tight margins. Investing in new management software, even when the long-term benefits are clear, can be hard to justify when cash flow is the immediate concern. By tying financing directly to a software subscription, this partnership removes one of the main reasons providers delay modernization.

The partners say the model is designed so that healthcare providers can adopt digital tools without additional financial pressure, while also improving how they run day-to-day operations and the quality of care they deliver to patients.

For EFG Holding and e-finance, both publicly listed companies, the deal also opens a new distribution channel. Egypt’s healthcare sector includes a large number of small, independent providers, and reaching them at scale requires local marketing infrastructure, which is exactly what eAswaaq brings.

The context

This deal fits into a broader push by the Egyptian government to advance digital transformation, expand financial inclusion, and grow the small business sector. Healthcare has been a specific area of focus, with several recent moves pointing in the same direction.

Just days before this announcement, Orange Egypt signed a separate agreement with eHealth to support digital health development in the country. That deal, announced on June 17, shows that eHealth is actively building a network of partners to scale up adoption of its platform.

Egypt’s healthcare sector has historically been slow to digitize compared to other industries. Most clinic management in smaller facilities still relies on manual processes, which creates inefficiencies in scheduling, billing, and patient records. Platforms like Eyada Plus are trying to change that, but adoption has been gradual. Pairing the software with accessible financing is a direct attempt to speed that process up.

The wider trend here is financial technology companies moving into sector-specific verticals rather than offering generic products. Combining lending with software subscriptions in a single package is a model that has worked in other markets, and Egypt’s healthcare sector appears to be the latest place where companies are trying to replicate it.

The post Tanmeyah, eHealth, and eAswaaq join forces to bring digital tools and financing to Egypt’s clinics appeared first on DH Arab.

The hospital, which is the flagship facility of Arabian Healthcare Group (AHG), says the platform will support clinical teams across cardiology, neurosciences, orthopaedics, spine surgery and urology. It pulls imaging data from across departments into one environment, giving doctors a fuller picture of a patient’s history without chasing down scans from different systems.

For patients, the practical benefit is straightforward: less waiting, fewer repeated tests and faster decisions from their care team. RAK Hospital currently sees more than 1,000 patients a day and reports patient satisfaction above 97 percent.

How does it work?

The platform creates a single, connected system for all imaging studies across the hospital network. Rather than radiologists and physicians working from separate, siloed systems, everything sits in one place. The AI layer on top of that does several things:

• Flags potential abnormalities in scans for radiologists to review
• Prioritises urgent cases so critical findings are not buried
• Speeds up reporting workflows, freeing clinicians to spend more time with patients

Critically, the platform is not limited to RAK Hospital’s own walls. It can read and integrate imaging data from external providers, including hospitals elsewhere in the UAE and internationally. That means a patient arriving with scans from another facility does not need to repeat those tests. Their prior imaging history is pulled into their record directly.

When AHG opens its new 209-bed Greenfield Hospital in 2027, along with a network of new medical centres across Ras Al Khaimah, all imaging data across those sites will feed into the same system. A doctor at one facility can instantly access scans taken at another, with no delay.

Why does it matter?

Medical imaging is one of the most data-heavy parts of healthcare, and also one of the most fragmented. Scans taken in one department often cannot be easily accessed in another. Patients who have had prior imaging at a different hospital frequently have to repeat tests from scratch, which costs time, money and in some cases delays treatment.

Connecting imaging data across an entire network, and extending that connection to outside providers, tackles a problem that affects almost every hospital system. Fewer repeated scans means lower costs. Faster access to prior results means clinicians can make decisions quicker. AI triage means the most urgent cases rise to the top.

For a hospital group in the middle of a major expansion, getting the data infrastructure right now, before the new facilities open, is a sensible move. Trying to integrate systems after the fact is far harder and more expensive.

The context

AI in medical imaging is one of the most active areas in health technology right now. Companies like PaxeraHealth compete with a growing number of vendors offering AI tools specifically designed to help radiologists handle increasing scan volumes without sacrificing accuracy. The global AI in medical imaging market is forecast to grow sharply through the end of the decade, driven by staff shortages, rising patient numbers and the push toward earlier diagnosis.

The UAE has been an active adopter of health technology across its major hospital networks, with government policy encouraging digital transformation in healthcare as part of broader national development goals. RAK Hospital’s investment fits that pattern, but the cross-network and cross-institution data sharing element is worth watching. Interoperability, the ability to share patient data cleanly between different providers and systems, has been one of healthcare’s hardest problems to solve. A platform that claims to handle external imaging from hospitals anywhere in the UAE or internationally is making a significant promise, and how well it delivers in practice will matter as much as the technology itself.

The post RAK Hospital rolls out AI imaging platform to speed up diagnosis appeared first on DH Arab.

The approach, called endoscopic nipple-sparing mastectomy, preserves the skin, nipple, and blood supply to the breast. Because the incision is placed under the armpit rather than on the breast itself, visible scarring is significantly reduced. Surgeons then reconstruct the breast through the same small opening before the patient wakes up.

KFSH says the service is now open to all patients at the Madinah facility, with referrals accepted from anywhere in Saudi Arabia. The hospital is also accepting cases for preventive surgery in women who carry high-risk genetic mutations linked to breast and ovarian cancer.

How does it work?

The surgery uses an endoscope, a small camera-equipped tube, inserted through a short incision hidden in the armpit. This lets surgeons remove affected breast tissue without cutting across the breast itself. The key steps are:

• A small incision is made under the armpit, out of sight
• The breast tissue is removed using the endoscope
• The skin, nipple, and blood supply are kept intact throughout
• Breast reconstruction is completed through the same incision before the operation ends

Because the procedure is minimally invasive, recovery is faster than with traditional open surgery. The hospital reports an average hospital stay of no more than two days, with patients returning to daily life sooner and reporting less pain during recovery.

Why does it matter?

Breast cancer surgery has long carried a psychological weight alongside the physical one. Losing a breast, or being left with significant scarring, affects self-image and emotional recovery for many patients. This technique directly addresses that by making visible changes to the body much harder to see.

KFSH reported 26 successful cases since the program’s clinical phase began in December 2023, with encouraging outcomes and high patient satisfaction. Those results were enough for the hospital to move from a trial phase to a permanent program.

The technique is available for two groups of patients:

• Women diagnosed with breast cancer who are eligible for mastectomy
• Women with high-risk genetic mutations, such as BRCA1 or BRCA2, who choose preventive surgery before cancer develops

This second group is particularly important. Preventive mastectomy is an option some women pursue after genetic testing reveals a significantly elevated cancer risk, and having a less visible surgical outcome can make that decision easier to consider.

The context

KFSH in Madinah already runs a breast conservation program that has helped reduce the rate of full mastectomies in the region. This new endoscopic program sits alongside that effort, giving surgeons and patients more options depending on the clinical situation.

The Madinah hospital has 400 beds and covers specialties including adult and pediatric oncology, ophthalmology, obstetrics, and gynecology. It holds 14 training accreditations across medical and nursing disciplines.

KFSH as a broader institution ranked first in the Middle East and Africa and 12th globally among the world’s top 250 academic medical centers for 2026, according to its own reporting. Brand Finance also named it the most valuable healthcare brand in Saudi Arabia and the Middle East for the same year. Newsweek listed it among the world’s best hospitals, best smart hospitals, and best specialized hospitals for 2026.

Nipple-sparing mastectomy with immediate reconstruction has been growing in adoption globally over the past decade as surgical tools and techniques have improved. Performing it endoscopically, through a remote incision rather than directly on the breast, is a newer refinement that fewer centers currently offer. KFSH making it a standard option puts the hospital among a relatively small group of facilities worldwide with this capability in routine clinical use.

The post Saudi hospital launches minimally invasive breast cancer surgery with same-day reconstruction appeared first on DH Arab.

The patient arrived with symptoms of cholangitis, a bacterial infection of the bile ducts. Scans revealed a tumor in the head of the pancreas blocking the bile duct, and a separate tumor in a section of the liver. A multidisciplinary team reviewed the case and decided to tackle both in one operation, accounting for the patient’s age and other health conditions.

KFSH announced the result on June 17, 2026, describing it as a significant case given how rarely these two cancers appear at the same time and how difficult they are to treat together.

How did it work?

The surgical team performed two separate but connected procedures in the same session:

• A pancreaticoduodenectomy, also called the Whipple procedure, which removes the head of the pancreas, part of the small intestine, the gallbladder, and part of the bile duct
• A partial hepatectomy, which removes the affected section of the liver
• Reconstruction of the digestive and biliary pathways to restore normal function after both removals

The robotic system gave surgeons high-definition, three-dimensional visuals and fine instrument control inside tight anatomical spaces where a small error can have serious consequences. The team included hepatopancreatobiliary surgeons, anesthesiologists, radiologists, gastroenterologists, oncologists, pathologists, critical care specialists, and nursing staff, all coordinating before, during, and after the operation.

Why does it matter?

Having cancer in both the pancreas and the liver at the same time is rare. Treating them together in one operation is harder still, because both organs sit in sensitive areas with major blood vessels nearby, and the reconstruction work after each removal adds its own risk. Traditionally, surgeons might have staged these as two separate open operations, which means two rounds of anesthesia, two recoveries, and more overall risk for an older patient with existing health problems.

Completing both in a single robotic session matters for a few reasons:

• One round of anesthesia instead of two reduces risk for the patient
• Robotic surgery typically means less blood loss and less physical trauma to surrounding tissue
• Recovery tends to be faster than after open surgery, which is important for a 74-year-old
• The hospital did not need to convert to open surgery, which is often a sign that the planning and execution went well

For the broader field, the case adds to the evidence that robotic platforms can handle compound cancer operations that would previously have been split up or avoided altogether in high-risk patients.

The context

Robotic surgery has been expanding steadily in oncology over the past decade. Early adoption focused on prostate and gynecological cancers, where the confined space and need for precision made the technology an obvious fit. More recently, hospitals have pushed into hepatopancreatobiliary surgery, one of the last areas where open surgery remained dominant because of the complexity involved.

KFSH is currently ranked first in the Middle East and North Africa and 12th globally among the world’s top 250 academic medical centers for 2026, according to its own rankings citation. Newsweek also listed it among the world’s best hospitals, best smart hospitals, and best specialized hospitals for 2026. The hospital has been building its robotic surgery program as part of a wider push in Saudi Arabia to develop advanced medical capabilities domestically, in line with the country’s Vision 2030 goals for the healthcare sector.

Pancreatic cancer in particular carries a poor prognosis partly because it is hard to detect early and hard to operate on safely. Cases where it appears alongside liver tumors are studied closely because the surgical and oncological decisions involved push the limits of what combined robotic procedures can achieve.

The post Saudi hospital removes pancreatic and liver tumors in a single robotic operation appeared first on DH Arab.

The agreement brings together two different skill sets. Orange Egypt contributes its telecom network, smart infrastructure, and digital channels. eHealth brings its health platforms and operational experience in the sector. Together, they plan to build service packages aimed at hospitals, clinics, and other healthcare providers.

Neither company disclosed financial terms or a timeline for when specific products or services would launch.

How will it work?

The MoU sets out several areas where the two companies plan to collaborate:

• Studying, designing, and developing integrated digital health solutions for healthcare providers
• Jointly operating and managing digital healthcare services
• Using Orange Egypt’s distribution network to expand access to healthcare institutions across the country
• Exploring interoperability between different health platforms and systems
• Looking for opportunities to partner with local and international companies and bid on digital health projects

In practice, Orange Egypt’s role is to put its existing customer relationships, infrastructure, and market reach behind eHealth’s platforms. The goal is to make it easier for healthcare institutions to adopt digital tools without having to build the underlying technology themselves.

Why does it matter?

Egypt has been pushing to modernize its healthcare system for several years, with digital infrastructure a key part of that effort. Deals like this one matter because they bring private sector players into that process, which can speed up deployment and reach more providers than government programs alone.

For Orange Egypt, this is part of a broader push by telecom operators across the Middle East and Africa to move beyond connectivity and into higher-value digital services. Healthcare is one of the most active sectors for that kind of expansion right now, given the pressure on health systems to do more with limited budgets.

For patients and healthcare workers, the practical upside is better integration between services. When hospitals, clinics, and insurers can share data through connected platforms, care tends to be faster and less prone to error.

The context

Egypt’s healthcare sector has been going through significant change. The country launched a universal health insurance system in 2018, and rolling that out across all governorates requires a strong digital backbone. That creates real demand for the kind of services Orange Egypt and eHealth are proposing.

Telecom companies across Africa have been signing similar deals in health, fintech, and government services as traditional voice and data revenues face pressure. Orange, the French parent group, has made digital services a central part of its Africa and Middle East strategy. Its Egyptian arm signing a deal in health fits that pattern.

eHealth, for its part, gets access to one of Egypt’s largest telecom networks and its existing relationships with enterprise clients. That kind of distribution is hard to build from scratch, and partnering with an established operator is a faster route to scale.

The post Orange Egypt and eHealth sign deal to build digital health services in Egypt appeared first on DH Arab.

The platform is built to do something doctors have long wanted: take vast amounts of fragmented clinical data and make it quickly searchable and useful in the middle of a patient consultation. Through a natural-language interface, physicians can ask questions and get answers that would otherwise take days of manual analysis.

The initial rollout focuses on prostate cancer, pulling together electronic health records, physician notes, pathology reports, and medical imaging into a single system a doctor can actually talk to.

How does it work?

Aila runs on Owkin’s agentic K Pro platform, which is purpose-built for biology and medical research. The core idea is straightforward: instead of siloed data sitting in separate systems, Aila connects those sources into one queryable layer.

Clinicians interact with it using plain-language questions, no technical queries required. The system then reasons across the connected data and returns insights in real time. It is also designed to keep learning as it processes more data over time.

The longer-term roadmap is ambitious:

• Expansion beyond prostate cancer into other medical specialties
• Support for more complex data types, including genomics and multi-omics data
• Integration into large-scale precision medicine programs

All of this runs on infrastructure supported by the UAE’s existing AI framework, which gives the platform room to scale.

Why does it matter?

The core problem Aila is trying to solve is one that frustrates clinicians everywhere. Patient data exists in abundance, but it is scattered across systems that do not talk to each other. A doctor trying to make a decision often has to piece together records manually, or simply work without the full picture.

If Aila works as described, it could meaningfully cut the time between data and decision. In cancer care especially, where treatment paths depend on combining imaging, pathology, genetics, and clinical history, that speed matters.

There is also a research angle. By connecting datasets at scale and making them queryable, the platform could help identify patterns across large patient populations that would be invisible to any individual physician reviewing individual cases.

The context

This launch fits into a much broader push by hospitals and health systems worldwide to move AI out of the lab and into actual clinical practice. Most AI health tools so far have focused on narrow tasks: reading a scan, flagging an anomaly, predicting a readmission. A platform designed to reason across multiple data types simultaneously is a step up in ambition.

Owkin has been building in this direction for several years, working with hospitals in Europe and the US on federated learning and AI-driven drug discovery. The Abu Dhabi collaboration is its most public deployment of an integrated clinical AI system.

The UAE has positioned itself aggressively as a hub for AI development, with national strategies and infrastructure investments designed to attract exactly this kind of project. Cleveland Clinic Abu Dhabi, a branch of the US-based Cleveland Clinic, brings the clinical credibility and patient data volume needed to make the platform viable from day one.

Whether Aila lives up to the ‘world’s first’ billing will depend on outcomes data. But as a signal of where hospital AI is heading, the launch is hard to ignore.

The post Cleveland Clinic Abu Dhabi launches ‘Aila,’ an AI platform billed as the world’s first clinical AI scientist appeared first on DH Arab.

The patient had developed a mutation in the ESR1 gene, a change that can make standard hormone therapy stop working and allow cancer to grow. Instead of waiting for scans or symptoms to confirm the disease was getting worse, doctors caught the mutation early using a blood test that detects cancer DNA circulating in the bloodstream. That early warning gave them the window they needed to switch to a more targeted treatment.

Camizestrant is not yet widely available in clinical settings, making this case significant both for the patient and for what it signals about Abu Dhabi’s push to bring advanced cancer treatments to patients faster than most health systems manage.

How does it work?

The key to this case is a technique called circulating tumour DNA monitoring, or ctDNA testing. When cancer cells die, they shed small fragments of DNA into the bloodstream. A blood test can pick up these fragments and look for specific mutations that suggest the cancer is changing or becoming resistant to treatment.

In this patient’s case, the test found an ESR1 gene mutation. This mutation is known to cause resistance to standard endocrine therapy, the type of hormone-blocking treatment commonly used for certain breast cancers. Catching it in the blood before it showed up on a scan gave doctors a critical head start.

Camizestrant works differently from standard endocrine therapy. It targets the oestrogen receptor in a more precise way, and is designed specifically to work even when the ESR1 mutation is present. By switching to it early, the clinical team aimed to:

• Keep the cancer under control for longer
• Delay further progression
• Protect the patient’s quality of life

Why does it matter?

The global SERENA-6 clinical trial provided the evidence behind this decision. That trial showed that patients with an ESR1 mutation who switched to Camizestrant had a 56% lower risk of disease progression or death compared to those who stayed on conventional endocrine therapy.

What makes SERENA-6 unusual is its design. It is the first large global trial to use serial ctDNA monitoring to trigger a treatment change before any visible or clinical sign of progression appears. That is a meaningful departure from the standard approach, which typically waits for scan results to confirm the cancer is growing before changing course.

Treating the molecular signal rather than waiting for visible disease gives oncologists an earlier intervention point, which could translate into better outcomes for patients with this type of mutation.

The context

Advanced breast cancer that is hormone receptor positive is one of the most common types of breast cancer diagnosed globally. For many patients, endocrine therapy works well initially, but ESR1 mutations are a well-documented reason it eventually stops working. Studies estimate that ESR1 mutations appear in roughly 30 to 40 percent of patients with hormone receptor positive, HER2 negative metastatic breast cancer who have been treated with aromatase inhibitors.

The broader trend here is precision oncology: using molecular data to make treatment decisions rather than relying solely on imaging or symptoms. Liquid biopsies, the umbrella term for blood-based tests like ctDNA monitoring, have been growing in clinical use for several years, but their role in actively guiding treatment switches in real time is still relatively new.

Abu Dhabi has positioned itself as a regional hub for this kind of advanced care, investing in diagnostic technology, clinical trial access, and specialist oncology infrastructure. Being the site of the world’s first clinical administration of Camizestrant fits that pattern, and reflects a broader push by the emirate to attract and deploy medical innovations ahead of most other health systems.

The post Abu Dhabi hospital gives world’s first clinical dose of new breast cancer drug appeared first on DH Arab.

Moadna, founded by Tarek Skheta and Maged Hamdeh, has raised $50,000 from angel investors, putting its valuation at $300,000. The company runs a platform that lets clinics and medical centres handle appointments, patient records, billing, and communications in one place.

The numbers are early-stage, but the traction is real. Moadna now has more than 550 doctors, clinics, and medical centres using its platform, over 8,000 registered users, and more than 3,500 appointments booked to date.

How does it work?

Moadna is built around two core needs: running a clinic and finding a doctor. On the provider side, it gives medical practices a single tool to manage their day-to-day operations, including:

• Appointment scheduling and calendar management
• Patient records and visit tracking
• Billing, revenue, and expense monitoring

For patients, the platform offers digital booking and direct communication with their healthcare providers. Think of it as a practice management system and a patient-facing booking app rolled into one.

Why does it matter?

Syria is not a market that gets much attention from tech investors. That makes this raise notable, even at a small scale. A homegrown startup building real infrastructure for healthcare providers in the country is a meaningful development, and the fact that it has attracted angel funding suggests at least some investors see opportunity there.

The funding will go toward three things: improving the product, strengthening the technical infrastructure, and expanding commercial operations. Moadna is also preparing for a pre-seed round, so this angel raise is a bridge to that next stage.

Healthcare digitisation across the Arab world is still patchy. While markets like Saudi Arabia and the UAE have seen serious investment in health tech, earlier-stage markets have far fewer options. Startups that can build reliable tools for clinics in those markets, and do it affordably, have a lot of room to grow.

The context

Moadna previously took part in Thimar, a startup support programme focused specifically on Syrian founders. That kind of structured support matters in markets where startup ecosystems are still forming and founders have fewer networks to draw on.

The company’s next step is a pre-seed round, which would give it the capital to push harder on growth inside Syria and potentially look at regional expansion. For now, the $50,000 raise is a signal that Moadna has enough momentum to bring outside capital in, even at an early stage.

The post Syrian healthtech Moadna raises $50,000 in angel funding appeared first on DH Arab.

The platform currently runs across five hospitals and serves more than 800 patients a day through 33 specialized clinics. Those clinics cover a range of services, including pediatric, orthopedic, neurological and mental health care.

The ministry says it plans to bring more hospitals and health centers onto the system in the coming months, gradually widening access to digital services across the country.

How does it work?

The portal gives patients online access to a set of core health services. Through the platform, users can:

• Book appointments at participating hospitals
• View their medical history and previous appointments
• Access laboratory results electronically

The goal is to cut down on the administrative work that typically falls on both patients and hospital staff, reducing waiting times and paperwork through a centralized digital system.

The portal currently operates at five hospitals:

• Damascus Hospital
• Ibn al-Nafees Hospital, Damascus
• Ibn al-Walid Hospital, Homs
• Hama National Hospital
• Tartous Maternity Hospital

Why does it matter?

For a country still rebuilding its health infrastructure after more than a decade of conflict, getting basic medical services to work reliably is a serious challenge. A functioning digital booking and records system is not a small thing in this context. It means fewer wasted trips to hospitals, less duplicated paperwork, and a clearer picture of patient histories for doctors.

The early numbers suggest real uptake. Over 114,000 patient enrollments in two months points to genuine demand, not just a system sitting idle after a launch announcement. Hitting 800 daily patients across 33 clinics also suggests the infrastructure is holding up under actual use.

The context

Syria’s health system took severe damage during the civil war, with hospitals destroyed, staff displaced, and supply chains disrupted. Rebuilding it digitally, rather than simply restoring the old paper-based model, is a deliberate choice that could pay off long-term.

Across the wider region, digital health adoption has been accelerating. Countries like Jordan, Saudi Arabia and the UAE have invested heavily in electronic health records and telemedicine over the past few years. Syria’s portal, modest as it is for now, puts the country on a similar path.

The Ministry of Health has framed the portal as part of a broader digital transformation strategy. How quickly that strategy moves beyond the current five hospitals will be the real test of whether the early momentum holds.

The post Syria’s digital health portal hits 118,000 visits in its first two months appeared first on DH Arab.

The device, called the AusculPatch, is a flexible sensor that sticks to the chest or over peripheral arteries and continuously picks up the mechanical vibrations produced by the heart, lungs, blood vessels, and pulse waves. It weighs 3.2 grams and measures roughly 20 by 47 by 3 millimetres, making it significantly smaller than most existing wearable health monitors.

The proof-of-concept research, led by Scientia Associate Professor Hoang-Phuong Phan and published in Nature Communications, describes how the patch was tested on a small group of healthy participants while they carried out everyday tasks including walking, eating, climbing stairs, and holding conversations. The team is now planning a much larger clinical trial.

How does it work?

At the core of the AusculPatch is an ultra-thin silicon sensing element. When the heart beats, it sends acoustic pressure waves through the body’s fluids and tissues. The sensing element picks up those tiny vibrations directly through the skin.

What sets this apart from a standard microphone is its frequency range. Conventional microphones are built to capture audible sound. This sensor can detect extremely low-frequency vibrations that are hard to pick up with current wearable technology, which means it can capture a broader set of physiological signals:

• Heart sounds, including subtle valve movements
• Breathing patterns
• Pulse waves
• Blood flow vibrations
• Blood pressure indicators

The team also designed the sensor to filter out environmental noise, a known weak point for acoustic wearables. “The sensor element is designed to shield the sound coming from one direction, typically from the human body,” said Tran Bach Dang, the study’s first author and a PhD candidate at UNSW’s School of Mechanical and Manufacturing Engineering. “In that way, it is less susceptible to ambient sound.”

In early tests, the patch showed strong agreement with established clinical tools including electrocardiograms, ultrasound scans, blood pressure monitors, and digital stethoscopes.

Why does it matter?

The problem the AusculPatch is trying to solve is straightforward. Most people with chronic heart or respiratory conditions are not being monitored between appointments. When they do see a doctor, the window is short.

“When they go to a clinic, patients often only have a 15-minute window for assessment,” said Dr Anthony Sunjaya, a medical doctor and Program Lead for Chronic Respiratory Disease at UNSW’s School of Population Health, who co-authored the study. “The danger is that the abnormalities experienced will not be fully recognised during that short period of time they are being seen.”

This is especially true for people in regional and remote areas, or those who are reluctant to visit hospital until symptoms become severe. By that point, outcomes are often worse even with treatment.

Continuous home monitoring could close that gap. The research team also sees significant potential in combining the patch with machine learning. Because the device collects large amounts of physiological data over time, an AI system could be trained to spot patterns that indicate a deterioration in health before the patient feels significantly worse.

“We can potentially apply machine learning to identify abnormal signals and warn the patients, and also notify their doctor,” said Dr Chi Cong Nguyen, an Associate Lecturer and co-corresponding author of the paper.

The context

Wearable health tech is a fast-growing market. Smartwatches and fitness trackers can already measure heart rate and blood oxygen levels, but they rely on optical sensors rather than acoustic ones. They give a relatively limited picture of what the heart and lungs are actually doing mechanically. The AusculPatch is trying to capture the kind of information that, until now, has mostly required clinical equipment and a trained clinician to interpret it.

The study is still at an early stage. The initial tests involved only a small number of healthy volunteers, and the patch has not yet been tested on people with the conditions it is designed to monitor. Larger studies are needed before anyone can draw firm conclusions about its clinical value.

That said, the UNSW team has a clear roadmap:

• A trial involving around 200 patients, including people with heart valve disease or implanted heart assist devices, is planned for later this year
• A follow-up study targeting around 1,000 patients is planned for subsequent years, focused on developing AI-assisted diagnostic tools
• Full regulatory approval for a medical-grade device is estimated to be around four to five years away
• A consumer wellness version of the technology could potentially arrive sooner

The researchers also demonstrated an early-stage application beyond cardiorespiratory monitoring: the patch can detect vocal cord vibrations through the throat. In proof-of-concept experiments, they used machine learning to recognise spoken words and wirelessly control a robotic arm, which could eventually support people with speech disorders or physical disabilities. That work is still at a very early stage, but it points to a broader range of possible uses for the underlying sensor technology.

The post This 3-gram patch could replace your doctor’s stethoscope appeared first on DH Arab.